Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 127 of 151

  1. TPIV200

    Marker Therapeutics

    Ovarian Cancer

    phase 2 mab completed

    1 trial

  2. TPM XR

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule completed

    1 trial

  3. TPX-0005-07

    Turn Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  4. TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostatic Neoplasms, Castration-Resistant

    phase 2 small molecule active

    1 trial

  5. TQB3616 capsules

    Chia Tai Tianqing Pharmaceutical Group Co.,

    HR-positive, HER2-negative Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  6. TQC2731 injection

    Shanghai University of Traditional Chinese Medicine

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  7. TQH2722 injection

    Shanghai University of Traditional Chinese Medicine

    Seasonal Allergic Rhinitis

    phase 2 small molecule active

    1 trial

  8. TRAP-BTC

    The George Institute

    cholangiocarcinoma or gallbladder carcinoma

    phase 2 small molecule active

    1 trial

  9. TRASTUZUMAB DERUXTECAN

    Fondazione Telethon ETS

    metastatic HER2-positive breast cancer patients

    phase 2 small molecule active

    1 trial

  10. TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN

    Ningbo Cancer Hospital

    Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.

    phase 2 small molecule active

    1 trial

  11. TRC105

    United Therapeutics Europe Ltd

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  12. TREAT LMNA

    Sana Biotechnology

    Laminopathies

    phase 2 small molecule active

    1 trial

  13. TREDIMIN 25.000 U.I. /2,5 ml soluzione orale

    Sana Biotechnology

    haematologic condition who need staminal cells transplant

    phase 2 small molecule active

    1 trial

  14. TREMELIMUMAB for locally advanced cholangiocarcinoma

    Fondazione Telethon ETS

    locally advanced cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  15. TREMELIMUMAB, DURVALUMAB

    The George Institute

    MSS and MSI colorectal and endometrial tumors

    phase 2 small molecule active

    1 trial

  16. TRI-001-01

    Ferring Pharmaceuticals

    Patients with Chronic Limb Threatening Ischemia (CLTI) due to Peripheral Arterial Disease (PAD)

    phase 2 small molecule active

    1 trial

  17. TRU-016 and bendamustine

    Aptevo Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule completed

    1 trial

  18. TRV734

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Use Disorder

    phase 2 small molecule completed

    1 trial

  19. TS-1 with cisplatin

    Hospital Authority, Hong Kong

    Recurrent Gastric Cancer

    phase 2 small molecule active

    1 trial

  20. TTI-101

    Tvardi Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  21. TTI-101

    Tvardi Therapeutics

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  22. TTI-101

    Tvardi Therapeutics

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  23. TTP054

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  24. TTP273

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  25. TTP399

    vTv Therapeutics

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    1 trial

  26. TTP399 400 mg

    vTv Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  27. TTP435

    vTv Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  28. TTP889

    vTv Therapeutics

    Coagulation

    phase 2 small molecule terminated

    1 trial

  29. TTP889

    vTv Therapeutics

    Venous Thromboembolism

    phase 2 small molecule completed

    1 trial

  30. TTX-MC138

    Transcode Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  31. TV-1380 150 mg

    Teva Pharma GmbH

    Cocaine Addiction

    phase 2 small molecule completed

    1 trial

  32. TV-45070

    Teva Pharma GmbH

    Postherpetic Neuralgia

    phase 2 small molecule completed

    1 trial

  33. TV-45070

    Teva Pharma GmbH

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  34. TV48574-IMM-20036

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  35. TVB-2640

    Sagimet Biosciences

    KRAS Gene Mutation

    phase 2 small molecule active

    1 trial

  36. TVB-2640

    Sagimet Biosciences

    Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  37. TVB-2640 25 mg (US)

    Sagimet Biosciences

    MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)

    phase 2 small molecule completed

    1 trial

  38. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Prophylaxis against renal transplant rejection

    phase 2 small molecule active

    1 trial

  39. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Kidney Transplant Rejection

    phase 2 mab active

    1 trial

  40. TYR300-101

    Tyra Biosciences

    Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations

    phase 2 other active

    1 trial

  41. TYR300-202

    Tyra Biosciences

    Non-muscle invasive bladder cancer (NMIBC)

    phase 2 other active

    1 trial

  42. TYRA-300

    Tyra Biosciences

    Locally Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  43. TYRA-300 0.125 mg/kg

    Tyra Biosciences

    Achondroplasia

    phase 2 small molecule active

    1 trial

  44. TYRA-300 60mg

    Tyra Biosciences

    Low-grade NMIBC

    phase 2 small molecule active

    1 trial

  45. Tabelecleucel

    Evidence Based Cataract Study Group

    Nasopharyngeal Carcinoma

    phase 2 mab terminated

    1 trial

  46. Tacrolimus

    Astellas Pharma Inc

    Bone Marrow Transplantation

    phase 2 small molecule completed

    1 trial

  47. Tacrolimus ointment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma

    phase 2 small molecule active

    1 trial

  48. Tafenoquine

    60 DEGREES PHARMACEUTICALS, INC.

    Babesiosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.